Feature | HRS | May 16, 2017

Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials

HRS presentations include data on the S-ICD, Micra, Nanostim, PV isolation, lead extractions and pharma

An electrophysiology EP ablation procedure to treat a heart arrhythmia

May 16, 2017 — Here is a list of the late-breaking clinical trials presented at the Heart Rhythm Society (HRS) 2017 annual meeting May 10-13, in Chicago. The data presented is for the latest in electrophysiology (EP) clinical research, techniques and technologies. These trials were featured at Heart Rhythm 2017 and will be published in the July issue of the Heart Rhythm Journal. 

Late-breaking Studies Presented at HRS 2017:

• The S-ICD Post-market Approval Study

Intra-nasal Etripamil For Conversion Of Paroxysmal Supraventricular Tachycardia (PSVT). Node-1 Trial

A Leadless Pacemaker In The Real-world Setting: The Micra Transcatheter Pacing System Post-approval Registry

• EWOLUTION trial: 1-Year Efficacy and Safety of Left Atrial Appendage Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation

High Incidence Of Previously Unknown (“Silent”) Atrial Fibrillation In Patients At High Risk For Atrial Fibrillation And Stroke: Primary Results From The REVEAL AF Study

Compliant Endovascular Balloon Reduces the Lethality of Superior Vena Cava Tears During Transvenous Lead Extractions

First-in-man Feasibility Study Of Subcutaneous Defibrillation Utilizing An Integrated Flexible String Shaped Defibrillator

PV Isolation With A Novel Multielectrode Radiofrequency Balloon Catheter That Allows Directionally-tailored Energy Delivery (RADIANCE): A Multicenter First-in-man Experience

• A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU (Apixaban Evaluation Of Interrupted Or Uninterrupted Anticoagulation For Ablation Of Atrial Fibrillation) Trial

• Long Detection Programming In Single Chamber Defibrillators Reduces Unnecessary Therapies And Mortality: The Advance III Trial

• SPECT-guided Left Ventricular Lead Placement For Improved CRT Efficacy: A Randomized Controlled Trial

• Ranolazine in High-Risk ICD Patients (RAID) Trial

• Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment In Subjects With Recurrent Atrial Fibrillation: Results From The Powder AF Multicentre Randomised Trial

• The Nanostim Leadless Pacemaker: Battery Failures and Worldwide Chronic Device Retrieval

 

Other Key Presentations:

VIDEO: Editor's Choice of Most Innovative New Technology at HRS 2017

VIDEO: EP Lead Extraction Strategies, interview with Bruce Wilkoff, M.D.

VIDEO: Current State of Leadless Pacemaker Technology, interview with Vivek Reddy, M.D.

VIDEO: Overview of Subcutaneous ICD Technology

VIDEO: How to Start an Electrophysiology Program

Expert Consensus Released on Catheter, Surgical Ablation of Atrial Fibrillation

Expert Consensus on MRI and Radiation Exposure in Patients With Implantable Cardiac Electronic Devices

Watch the VIDEO "Current State of Atrial Fibrillation Technologies," an interview with Dr. Hugh Calkins.

Watch the VIDEO interview with HRS President Michael Gold, M.D., on latest EP technology trends

 

Link to Heart Rhythm 2018 Late-breaking Studies
 

For more information: www.hrssessions.org

Related Content

An example of the new generation of cardiac monitoring device that is replacing Holter monitoring is the Cardea Solo wearable sensor. The FDA-cleared device automatically analyzes data when the device is turned back into the physician's office and automatically produces a draft summary report. This technology can simplify the workflow by eliminating the need for third-party involvement.

Feature | Atrial Fibrillation | September 13, 2018 | Melissa Sersland
Rapid advances in technology to monitor atrial fibrillation (AF or Afib) are enabling clinicians to access real-time
Atrial Fibrillation Patients Diagnosed With Carotid Atery Disease Face Increased Risk of Dementia

Image courtesy of Intermountain Medical Center Heart Institute

News | Atrial Fibrillation | May 24, 2018
Atrial fibrillation patients who are diagnosed with carotid artery disease face higher risks for developing dementia,...
Botulinum Toxin (botox) Injection in CABG Patients Reduces AFib After Cardiac Surgery. #HRS2018

Figure 1: At the end of 36 months, the incidence of any atrial tachyarrhythmia was 23.3 percent in the botox group, as compared to 50 percent in the placebo group

News | Atrial Fibrillation | May 18, 2018
 
Atrial fibrillation ablation using the Abbott Ensite electro mapping system. CABANA Trial Confirms Ablation Equal To or Superior to Drug Therapy. #HRS2018

Atrial fibrillation ablation using the Abbott Ensite electro mapping system.

Feature | Atrial Fibrillation | May 17, 2018
May 16, 2018 – The first results of the randomized, multicenter, long-term, international...
Link Found Between Post-Traumatic Stress, Increased Risk of AFib. #HRS2018
News | Atrial Fibrillation | May 15, 2018
May 15, 2018 — A new study is the first to report a relationship between post-traumatic stress disorder (PTSD) and ne
Marijuana Use Does Not Increase Risk of Arrhythmias, Might Reduce AFib Risk. #HRS2018
News | Atrial Fibrillation | May 15, 2018
May 15, 2018 — According to new research, smoking marijuana may not be associated with an increased risk of ventricul
First Results Reported from AVIATOR 2 Registry for AFib Patients Undergoing PCI.

Photo courtesy of the American Heart Association

News | Atrial Fibrillation | May 15, 2018
May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception a
New Combined Risk Score More Effectively Predicts Stroke Risk in AFib Patients

Image courtesy of Intermountain Medical Center Heart Institute

News | Atrial Fibrillation | May 11, 2018
A new study finds that integrating two separate clinical risk score models more accurately helps clinicians assess the...
Depression Linked to Increased Atrial Fibrillation Risk
News | Atrial Fibrillation | March 27, 2018
March 27, 2018 — Depression may increase the risk for...
Overlay Init